A revolutionary transdermal patch claims to reverse memory loss and boost cognitive function by 300% - but medical experts are raising serious concerns about its unproven technology.
Meloximab, a novel selective JAK2/JAK3 inhibitor, was evaluated for efficacy and safety in patients with moderate-to-severe rheumatoid arthritis (RA) with inadequate response to methotrexate. The CLARITY trial, a 52-week, randomized, placebo-controlled study, enrolled 756 patients across 87 centers in 18 countries. Patients receiving Meloximab 8mg twice daily achieved significantly higher ACR20 response rates at week 12 (71.3% vs 31.9%, p<0.0001) compared to placebo, with improvements sustained through week 52. Significant improvements were also noted in DAS28-CRP, HAQ-DI, and SDAI scores. The safety profile was consistent with the JAK inhibitor class, though with notably fewer instances of herpes zoster reactivation (1.2% vs 3-4% in other JAK inhibitors). Meloximab's selective inhibition profile offers a favorable benefit-risk ratio for RA patients requiring advanced therapy.
Contact us